Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4452656 | 0.85 | PKM (0.35) | — | |
| SCHEMBL4462974 | 0.73 | ITGB3 (0.38) | ALDH1A1 | |
| SCHEMBL4450975 | 0.72 | MAPK1 (0.38) | — | |
| SCHEMBL6551536 | 0.64 | THRA (0.31) | — | |
| SCHEMBL719443 | 0.59 | FABP3 (0.41) | ALDH1A1TSHR | |
| SCHEMBL3925075 | 0.59 | CA1 (0.39) | ALDH1A1 | |
| SCHEMBL27693776 | 0.59 | KDM4E (0.36) | ALDH1A1 | |
| SCHEMBL9425114 | 0.58 | SLC9A1 (0.31) | — | |
| Hydrochloric Acid SCHEMBL1005423 | 0.58 | FABP3 (0.40) | TSHR | |
| SCHEMBL10435622 | 0.58 | L3MBTL1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538216-B2 | Guanidino phenylalanin compounds used as urokinase inhibitors | WILEX AG (DE) | 2009-05-26 | — | — | US | disclosed |
| US-20050267127-A1 | Guanidino phenylalanin compounds used as urokinase inhibitors | WILEX AG (DE) | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267127-A1 | Guanidino phenylalanin compounds used as urokinase inhibitors | PLAU, PLAUR, ENPEP | KEAP1 1298/4885NFE2L2 3697/4885ALDH1A1 1671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.